R
Richard Bourgon
Researcher at Genentech
Publications - 82
Citations - 17336
Richard Bourgon is an academic researcher from Genentech. The author has contributed to research in topics: Cancer & DNA methylation. The author has an hindex of 34, co-authored 80 publications receiving 13059 citations. Previous affiliations of Richard Bourgon include European Bioinformatics Institute & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan,Shannon J. Turley,Dorothee Nickles,Alessandra Castiglioni,Kobe C. Yuen,Yulei Wang,Edward E. Kadel,Hartmut Koeppen,Jillian L. Astarita,Rafael Cubas,Suchit Jhunjhunwala,Romain Banchereau,Yagai Yang,Yinghui Guan,Cecile Chalouni,James Ziai,Yasin Senbabaoglu,Stephen Santoro,Daniel Sheinson,Jeffrey Hung,Jennifer M. Giltnane,Andrew A. Pierce,Kathryn Mesh,Steve Lianoglou,Johannes Riegler,Richard A.D. Carano,Pontus Eriksson,Mattias Höglund,Loan Somarriba,Daniel L. Halligan,Michiel S. van der Heijden,Yohann Loriot,Jonathan E. Rosenberg,Lawrence Fong,Ira Mellman,Daniel S. Chen,Marjorie C. Green,Christina Louise Derleth,Gregg Fine,Priti S. Hegde,Richard Bourgon,Thomas Powles +41 more
TL;DR: Tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent were examined and major determinants of clinical outcome were identified and suggested that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
Recurrent R-spondin fusions in colon cancer
Somasekar Seshagiri,Eric Stawiski,Steffen Durinck,Zora Modrusan,Elaine E. Storm,Caitlin B. Conboy,Subhra Chaudhuri,Yinghui Guan,Vasantharajan Janakiraman,Bijay S. Jaiswal,Joseph Guillory,Connie Ha,Gerrit J. P. Dijkgraaf,Jeremy Stinson,Florian Gnad,Melanie A. Huntley,Jeremiah D. Degenhardt,Peter M. Haverty,Richard Bourgon,Weiru Wang,Hartmut Koeppen,Robert Gentleman,Timothy K. Starr,Zemin Zhang,David A. Largaespada,Thomas D. Wu,Frederic J. de Sauvage +26 more
TL;DR: The R-spondin gene fusions, several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3 are identified and shown to be capable of potentiating Wnt signalling.
Journal ArticleDOI
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan,Bijay S. Jaiswal,Jeremy Stinson,Vasantharajan Janakiraman,Deepali Bhatt,Howard M. Stern,Peng Yue,Peter M. Haverty,Richard Bourgon,Jianbiao Zheng,Martin Moorhead,Subhra Chaudhuri,Lynn P. Tomsho,Brock A. Peters,Kanan Pujara,Shaun Cordes,David Davis,Victoria Carlton,Wenlin Yuan,Li Li,Weiru Wang,Charles Eigenbrot,Joshua S. Kaminker,David A. Eberhard,Paul Waring,Stephan C. Schuster,Zora Modrusan,Zemin Zhang,David Stokoe,Frederic J. de Sauvage,Malek Faham,Somasekar Seshagiri +31 more
TL;DR: This study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets.